<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193088</url>
  </required_header>
  <id_info>
    <org_study_id>INC-6602</org_study_id>
    <secondary_id>1U54NS065712-01</secondary_id>
    <nct_id>NCT01193088</nct_id>
  </id_info>
  <brief_title>Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2</brief_title>
  <acronym>INC-6602</acronym>
  <official_title>Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydney Children's Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project includes two projects. One is looking for new genes that cause Charcot Marie
      Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify
      the symptoms a person has.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is to understand modifier genes and how they influence the severity of disease
      expression, along with identifying new forms of CMT which have not been genetically
      determined. Subjects who are eligible will either have CMT type 1A (CMT1A) or an unknown
      form of CMT. Blood will be drawn and sent to the University of Miami where they receive the
      coded sample and process it through exome sequencing. Subjects will be told that this is
      optional.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Charcot Marie Tooth disease type 1A (CMT1A) gene modifiers</measure>
    <time_frame>once</time_frame>
    <description>While the same genetic change - an extra copy of PMP22 - causes CMT1A by definition, it is unclear why some people have more severe symptoms and some have less severe. We are looking for genetic modifiers - changes in the DNA that may be causing the differences in symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New genetic causes of CMT</measure>
    <time_frame>Once</time_frame>
    <description>At least 33% of people with CMT have an unknown or genetically un-found form of the condition. We are looking for additional genes that cause CMT when mutated.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Charcot-Marie-Tooth Disease, Type Ia (Disorder)</condition>
  <condition>HMSN</condition>
  <arm_group>
    <arm_group_label>CMT1A</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Genetically undefined CMT</arm_group_label>
    <description>Families/people with genetically undefined CMT with common causes ruled out.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA extracted from whole blood. Filter cards with blood spots.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients participating in Inherited Neuropathies Consortium (INC)-6601 and meeting
        eligibility criteria for this study will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient MUST be seen in person at one of the clinical sites involved in this study.

        Charcot Marie Tooth disease type 1A (CMT1A) modifier gene study

          -  Patient has a documented PMP22 duplication OR

          -  Patient has a first or second degree relative (parent, child, sibling, half-sibling,
             aunt, uncle, grandparent, grandchild, niece, or nephew) with a documented PMP22
             duplication AND a clear link between that family member and the affected patient AND
             a phenotype consistent with CMT1A.

             i. A clear link is necessary for a second-degree relative. For example, if a
             grandparent is affected and has a PMP22 duplication, and the parent does not have any
             signs, symptoms, or electrophysiology consistent with CMT1A, there is no clear link.

        ii. In cases where clear links are not available, genetic testing is required for the
        patient or the first degree family member who is not clearly affected.

        AND

          -  Patient has agreed to take part in the study and has signed a consent form.

          -  A teenager (ages 13-17) considering enrolling must agree to take part in the study
             and sign an assent form

        Inclusion Criteria - CMT Exome Project

          1. Patient has demonstrated neuropathy on nerve conduction studies or a clinically
             diagnosed genetic neuropathy.

          2. Patient or first or second degree family member with a clear link as described in the
             CMT1A Inclusion Criteria part b has had negative MFN2 genetic testing, if has an
             axonal form of CMT (nerve conductions greater than 38 m/s) or negative testing for
             PMP22 duplication, deletion, sequencing, MPZ, and GJB1 if a demyelinating form of CMT
             is present (&lt;38 m/s).

          3. More than one family member is willing eligible to participate.

        i. Sample pedigrees showing optimal degrees of relationship are shown below. ii.
        Participation includes being able to complete all aspects of the study, including the
        giving informed consent, having a brief physical examination, and providing a DNA sample.

        d. Patient has agreed to take part in the study and has signed a consent form. e. A
        teenager (ages 13-17) considering enrolling must agree to take part in the study and sign
        an assent form.

        Inclusion Criteria - Controls

          1. Person does not have a peripheral neuropathy, as determined by the investigator.

          2. Person has understood the study and signed an IRB approved consent form. Teenagers
             (age 13-17 years) must sign an assent form.

        Exclusion Criteria:

          1. Patient does not wish to participate or does not sign a consent form.

          2. For CMT Exome Project, patient has a genetically confirmed form of CMT (i.e. mutation
             in MFN2 causing CMT2A, mutation in GARS causing CMT2D, etc.).

          3. Known neuropathy from a non-genetic source, such as chemotherapies (i.e. Vincristine,
             Taxol, Cisplatin), diabetes, alcoholism will be evaluated independently so that
             genetic contributions to their effects on CMT1A phenotypes can also be analyzed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E Shy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawna Feely, MS, CGC</last_name>
    <phone>319-384-6362</phone>
    <email>UICMTClinic@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Grider, MS, CGC</last_name>
    <phone>319-384-6362</phone>
    <email>UICMTClinic@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Allred</last_name>
      <phone>310-423-4268</phone>
      <email>Peggy.Allred@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Siskind, MS, LCGC</last_name>
      <phone>310-423-4268</phone>
      <email>CSiskind@Stanfordmed.org</email>
    </contact>
    <investigator>
      <last_name>John Day, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Henry</last_name>
      <email>Kelly.Bates@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Feely, MS, CGC</last_name>
      <phone>319-384-6362</phone>
      <email>UICMTClinic@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Michael E Shy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kelley</last_name>
      <phone>443-287-0627</phone>
      <email>akelle12@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Lloyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Sumner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bogue</last_name>
      <phone>734-647-3863</phone>
    </contact>
    <investigator>
      <last_name>Sindhu Ramchandren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Sowden</last_name>
      <phone>585-275-1267</phone>
      <email>janet_sowden@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>David Herrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donnette Paris</last_name>
      <phone>267-426-7167</phone>
      <email>Paris@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Richardson</last_name>
      <phone>215-349-5313</phone>
      <email>Jessica-Richardson@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Scherer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Alexander</last_name>
      <phone>615-936-0060</phone>
    </contact>
    <investigator>
      <last_name>Jun Li, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98124-1889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrie Smith, MS</last_name>
      <phone>206-598-3462</phone>
      <email>corrieo@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Bird, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Westmead</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Gabrael</last_name>
      <phone>+61 2 9845 1904</phone>
      <email>natalig1@chw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Joshua Burns, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C. Besta Neurological Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Marchesi</last_name>
      <phone>+39-02 2394 3001</phone>
      <email>chiara.marchesi@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Davide Pareyson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital of Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacky Molyneaux,</last_name>
      <phone>+44 207 380 6852</phone>
      <email>j.molyneaux@ion.ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mary Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/INC/</url>
    <description>Inherited Neuropathies Consortium Website</description>
  </link>
  <results_reference>
    <citation>Montenegro G, Powell E, Huang J, Speziani F, Edwards YJ, Beecham G, Hulme W, Siskind C, Vance J, Shy M, ZÃ¼chner S. Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol. 2011 Mar;69(3):464-70. doi: 10.1002/ana.22235. Epub 2011 Jan 20.</citation>
    <PMID>21254193</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 14, 2015</lastchanged_date>
  <firstreceived_date>August 9, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Michael Shy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CMT</keyword>
  <keyword>CMT1A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>4-des-dimethylaminotetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
